12:00 AM
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Oral methylnaltrexone: Phase III started

Progenics began a double-blind, placebo-controlled, international Phase III trial to evaluate 3 doses of oral methylnaltrexone in 700 patients. Prior to being acquired by Pfizer last October, Wyeth returned rights for...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >